Marubeni Corporation, a major Japanese integrated trading and investment business conglomerate, has acquired a minority stake in Lunatus, one of the largest and fastest growing pharmaceutical companies in the MENA region.
Lunatus, based in Dubai, is a market-leading turnkey solutions provider for international pharmaceutical and medical device companies, handling regulatory, marketing, sales, distribution, and supply chain management. With the intention to expand the network globally, Marubeni identifies the growth potential in pharmaceutical-related businesses and medical service businesses in the Middle East.
Through the broad regional Lunatus network, Marubeni will bridge the Japan-Middle East markets and will bring Japanese high-quality pharmaceuticals and medical devices to the Middle East to accommodate the increasing demand in the region. Moreover, by leveraging their joint expertise, Marubeni and Lunatus intend to expand the business across the other emerging markets including ASEAN and Africa.
“Over the last 19 years, we have built one of the largest regional pharmaceutical companies spanning the GCC and Levant regions. We are thrilled to partner with Marubeni in further consolidating and expanding our footprint as we explore unique growth opportunities regionally and in the Asian markets. This transaction presents a unique strategic opportunity to partner alongside Marubeni, a global conglomerate, in further growing the Lunatus brand.”
Mr. Eisuke Kamide, General Manager of Marubeni’s Healthcare & Medical Business Department, commented that “We are proud to form a strategic alliance partnership with Lunatus, and will continue exploring opportunities in the Middle East pharmaceutical market. Marubeni is focused on the MENA market which has large growth potential, and this transaction will enable us to expand our pharmaceutical and medical device business network from China to the Middle East and Africa. Through these efforts, we would like to reduce the healthcare disparity globally and regionally, bringing value to all patients, families and stakeholders.”